Jackie07
12-14-2011, 04:24 AM
Just received the following from BCT (https://www.breastcancertrials.org/bct_nation/home.seam (https://www.breastcancertrials.org/bct_nation/home.seam)):
Dear BCT Community:
Scientists, clinicians, and patients from all over the world gathered last week for the 34th annual San Antonio Breast Cancer Symposium. Among the highlights of this year's conference:
Zoledronic Acid (Zometa) shows long-term benefit in survivorship for pre-menopausal women
Dual HER2 blockade significantly extends progression-free survival (Cleopatra Trial)
Exemestane Plus Everolimus increases progression-free survival for women with metastatic breast cancer
New test predicts risk for recurrence for patients with DCIS
The editors and staff of Cure Magazine (http://www.curetoday.com/) have been covering the conference by highlighting news through daily written and video blogs. They will be sending out a comprehensive email detailing all their stories on December 15. In order to learn more about the findings presented at the San Antonio Breast Cancer Symposium, sign-up here (http://r20.rs6.net/tn.jsp?llr=t4xakreab&et=1108957508231&s=1557&e=001CjlWqgViCPfmnFkaspHsfpYsFspb8ruJe7jlbWUdcSsyJ dNdvyvvdKjiDfnQAUra2T8BlloE4x-CvEnbmSsNa3uO46MLLSaOJbpmDWhDF70OiHRzrTyIehsJt8_HR CHGETA-2JI3xbqVYoeivvHKpQ==) to receive this email from Cure Magazine.
Sincerely,
The BCT Team
Dear BCT Community:
Scientists, clinicians, and patients from all over the world gathered last week for the 34th annual San Antonio Breast Cancer Symposium. Among the highlights of this year's conference:
Zoledronic Acid (Zometa) shows long-term benefit in survivorship for pre-menopausal women
Dual HER2 blockade significantly extends progression-free survival (Cleopatra Trial)
Exemestane Plus Everolimus increases progression-free survival for women with metastatic breast cancer
New test predicts risk for recurrence for patients with DCIS
The editors and staff of Cure Magazine (http://www.curetoday.com/) have been covering the conference by highlighting news through daily written and video blogs. They will be sending out a comprehensive email detailing all their stories on December 15. In order to learn more about the findings presented at the San Antonio Breast Cancer Symposium, sign-up here (http://r20.rs6.net/tn.jsp?llr=t4xakreab&et=1108957508231&s=1557&e=001CjlWqgViCPfmnFkaspHsfpYsFspb8ruJe7jlbWUdcSsyJ dNdvyvvdKjiDfnQAUra2T8BlloE4x-CvEnbmSsNa3uO46MLLSaOJbpmDWhDF70OiHRzrTyIehsJt8_HR CHGETA-2JI3xbqVYoeivvHKpQ==) to receive this email from Cure Magazine.
Sincerely,
The BCT Team